Estudio SOGUG-TRIDA el triplete Darolutamida-Docetaxel-TDA en mHSPC confirma su valor en una población de vida real con peores características que las del estudio ARASENS, no alcanzar respuesta profunda de PSA (>0,2ng/ml) se confirma como endpoint desfavorable #ESMO2026 @sogug1
24 views · 2 likes · 0 reposts · 0 replies
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.orgSource: Ricardo Sánchez-E · x.com